Cargando…
Development of a penem antibiotic against Mycobacteroides abscessus
β-lactams are the most widely used antibiotic class to treat bacterial infections in humans. Mycobacteroides abscessus is an emerging pulmonary pathogen resistant to most antibiotics, including penicillins and cephalosporins. With no current FDA-approved treatment and cure rates <50%, there is a...
Autores principales: | Batchelder, Hunter R., Story-Roller, Elizabeth, Lloyd, Evan P., Kaushik, Amit, Bigelow, Kristina M., Maggioncalda, Emily C., Nuermberger, Eric L., Lamichhane, Gyanu, Townsend, Craig A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7721803/ https://www.ncbi.nlm.nih.gov/pubmed/33288821 http://dx.doi.org/10.1038/s42003-020-01475-2 |
Ejemplares similares
-
T405, a New Penem, Exhibits In Vivo Efficacy against M. abscessus and Synergy with β-Lactams Imipenem and Cefditoren
por: Rimal, Binayak, et al.
Publicado: (2022) -
A mouse model of pulmonary Mycobacteroides abscessus infection
por: Maggioncalda, Emily C., et al.
Publicado: (2020) -
Potency of Omadacycline against Mycobacteroides abscessus Clinical Isolates In Vitro and in a Mouse Model of Pulmonary Infection
por: Nicklas, Danielle A., et al.
Publicado: (2022) -
Glby, Encoded by MAB_3167c, Is Required for In Vivo Growth of Mycobacteroides abscessus and Exhibits Mild β-Lactamase Activity
por: Galanis, Christos, et al.
Publicado: (2022) -
Mycobacterium abscessus and β-Lactams: Emerging Insights and Potential Opportunities
por: Story-Roller, Elizabeth, et al.
Publicado: (2018)